After successfully completing the end-of-phase II meeting with the U.S. Food and Drug Administration (FDA), the phase III clinical trial plan for BPL-003 is progressing steadily and is expected to officially launch in the second quarter of 2026.

After successfully completing the end-of-phase II meeting with the U.S. Food and Drug Administration (FDA), the phase III clinical trial plan for BPL-003 is progressing steadily and is expected to officially launch in the second quarter of 2026.

老虎证券2026/03/10 10:07

Show original

This significant development marks a critical stage in the drug development project. Meanwhile, Atai Beckley Inc (referred to as Atai Beckley) highlighted several key milestones in its research and development pipeline at the recently held 2026 Investor Day event. The company's management elaborated on the strategic layout and expected progress for the coming years, demonstrating its firm commitment to advancing innovative therapies.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

PoolX: Earn new token airdrops

Lock your assets and earn 10%+ APR

Lock now!

After successfully completing the end-of-phase II meeting with the U.S. Food and Drug Administration (FDA), the phase III clinical trial plan for BPL-003 is progressing steadily and is expected to officially launch in the second quarter of 2026.

You may also like

Trending news

Crypto prices